Glial neoplasms are the most common primary intracranial malignancies. Treatment of highgrade gliomas has been frustrating, with less than 5% of patients surviving 5 years after a diagnosis of glioblastoma multiforme (GBM). Stereotactic radiosurgery (SRS) and fractionated strereotactic radiotherapy (F-SRT) provide means to either escalate the dose in primary treatment or to palliate recurrences. Because of their lower aI~ratios and more focal nature, low-grade gliomas (LGG) are more attractive targets for stereotactically focused radiation.
Introduction
Glial neoplasms are the most common primary intracranial malignancies. Of these, glioblastoma multiforme (GBM) represent the most common subtype (1). Despite the use of surgery, radiation and chemotherapy, long-term survival of patients with GBM is distinctly uncommon. In unselected series, the 5 year survival is as low as 2% (2, 3) . GBM is a local disease. Distant spread being a rare event and 90% of recurrences are located within 2 em of the original enhancing lesion (4) (5) (6) (7) . Anaplastic astrocytoma (AA) represent less than 20% of malignant gliomas and are associated with a more favorable outcome (I, 8) . Five to 10% of gliomas are low-grade lesions. Patients with low-grade gliomas form a very heterogeneous population. Outcome is highly depend on age and performance status (9) : overall pediatric patients can expect a 90% 4-year survival (10) , whereas patients over 40 with a poor performance status have a median survival of only 12 months.
Infiltrating glial neoplasms would appear to be poor candidates for the stereotactic application of single fraction irradiation. These tumors are hypoxic, acute-responding (II) and admixed with normal tissue (12, 13) . Despite these biological roadblocks stereotactic radiation has been pursued in the management of HGG. The use of radiosurgery has been based on the pattern of failure of this disease, the doseresponse data from external beam radiation and early data from interstitial brachytherapy trial (14, 15) . Low-grade gliomas may be less infiltrative and have a lower a/~ratio (16) but they have failed to demonstrate a better response to increasing radiation doses.
Single fraction stereotactic radiation (or stereotactic radiosurgery (SRS)) has predominantly been used in one of two treatment plans: in primary lesions as a supplement to wider volume external-beam radiation (EBRT) and in recurrent lesions as a single modality. With the advent of non-invasive immobilization devices, the use of fractionated stereotactic radiation therapy (F-SRT) has become more common.
The use of stereotactic radiation in HGG has previously been reviewed (17) (18) (19) (20) (21) (22) (23) (24) (25) (26) (27) (28) (29) (30) (31) (32) . In this review we will rehash much of the same data but hopefully add a new perspective in view of recent preliminary results of randomized trials.
Stereotactic Radiosurgery in the Primary Management of High-grade Gliomas
The 90s saw the publication on several small series of patients treated with SRS boost in the primary treatment of malignant glioma (Table I) . Overall the median survival of patients treated with SRS was quite encouraging. However, in a disease where more than 95% of patients will ultimately die of their disease, the median survival is dictated more by patientrelated than therapy-related factors (8) . By the very nature of SRS, patients are selected for: small tumors, more complete resection (size determination being based on post operative imaging) and a good response to initial therapy (when SRS is administered after EBRT, patients with progressive disease are likely to be excluded). In addition, trials commonly require a good performance status (KPS of 50 (33) , 70 (34, 35) or 90 (36) ). Other potential sources of bias include high patient motivation, more favorable tumor biology and aggressive treatment of recurrences. Only one tenth to one quarter of GBM patients-will be eligible for radiosurgical boost (37) .
Roberge and Souhami
The results of radiosurgical series were viewed with skepticism. In an attempt to reduce bias authors sought out retrospective control populations. One of the largest reviews (38) attempted to retrospectively stratify lIS patients from 3 institutions (Harvard, the University of Florida and the University of Wisconsin) according to the prognostic classes of the RTOG recursive partitioning analysis of patients enrolled on RTOG 74-0 I, 79-18 and 82-02 (39) (40) (41) . This analysis concluded that there was a significant improvement in both 2-year and median. survival favoring SRS-treated patients. Unfortunately, along with other flaws, the RTOG classes used were broad, did not include all prognostic factors (most notably -tumor size) and converted important linear variable into binary ones (age, mental status and KPS). Thus, this approach, along with all retrospective comparisons is inherently flawed. Irish et al. published an elegant analysis of 10I consecutive patients seen at the London regional cancer center. Of these 27% were deemed eligible for radiosurgery. The median survival of these patients was 23.4 months compared to 8.6 for the radiosurgery ineligible patients. This study highlights the significant effects of patient selection. It also demonstrates that a patient group can be selected that performs better than the most favorable group in the RTOG recursive partitioning analyses -the RTOG class 111 patients (GBM age > 50, KPS~90) for whom the median survival is 18 months. The bottom line is that only randomization can control efficiently for all confounding factors.
Having previously demonstrated the feasibility of a multiinstitutional radiosurgery trial (42) and encouraged by the favorable survival of patients treated on phase IIII protocols, the RTOG opened protocol 93-05 in 1993. This was a prospective randomized trial evaluating upfront SRS followed by EBRT with BCNU (Arm I) vs. EBRT and BCNU (Arm 2).
Eligibility criteria required patients to be at least 18 years of age, have a KPS of at least 60% and to have a histologically proved supratentorial, unifocal GBM. All lesions were to be 4cm or less in maximal diameter.
In the investigational arm radiosurgery was to be given up front, within 5 weeks of surgery. The SRS was prescribed to the isodose surface (50% to 90%) encompassing the enhancing portion of the tumor. The prescription dose varied with tumor volume and was 24, 18 or 15 Gy for maximal tumors diameters of s 20mm, 21-30mm and 31-40mm respectively.
External beam radiation was the same in both arms: a volume encompassing the tumor, surrounding edema and a margin was treated to 60 Gy with daily fractions of 2 Gy. BCNU was administered at a dose of 80mg/m2 on days 1,2,3 of EBRT and then repeated every 8 weeks for a total of 6 cycles.
The first patient was treated in February 1994 and the study was closed in June 2000 after the 203 rd patient was enrolled Thus the best evidence currently available does not support an improvement in median survival following the addition a SRS to a standard treatment regimen for GBM. There is also no evidence of an improvement in quality of life or a change in pattern of failure. There is however an increase in both acute and late radiation related toxicity. These results are not surprising in a disease where surgical excision of the radiosurgery target is not curative. Effects of SRS on long-term survival will have to await further follow-up but published retrospective studies do not suggest an improvement in 5-year survival.
Single Fraction Stereotactic Radiosurgery for Recurrent High-grade Gliomas
Treatment of recurrent high-grade glioma is essentially palliative. Strategies available (44) include reoperation, chemotherapy, EBRT reirradiation, SRS, F-SRT, interstitial brachytherapy, supportive care, .... Each of these modalities has its own toxicities and indications. Currently published Phase III studies support an improvement in median survival from the use of BCNU polymers (45) and an improvement in softer measures of outcome from the use of oral temozolomide (44, 46, 47) . There are no phase III trials of radiosurgery for recurrent tumors.
A 1994 series from the University of California San Diego included 15 patients were with recurrent high-grade gliomas. Doses prescribed ranged from 12-15Gy based on the target volume. Of the total group of 20 patients, 7 have suffered intra-cranial pressure related acute toxicity (fatal in one patient) and I has suffered from a late somnolence syndrome. Outcome was not reported by tumor type.
In 1995, the experience of the University of Minnesota was published (48) . 35 recurrent tumors (26 GBM, 9 AA) had been treated with single doses of radiation . The median survival for all patients from the time of SRS was 8 months. The actuarial rate of necrosis requiring surgery was 14% (the overall reoperation rate was 31%). Despite SRS, 85% of recurrences were local or marginal.
Kondziolka et al. reported on the University of Pittsburgh experience treating 42 patients with recurrent high-grade gliomas (33) . Median survival from radiosurgery was very favorable, 30 months for GBM, 31 for AA. There were no cases of acute toxicity and three patients experiences late radiosurgery-related morbidity. Overall 22/l 07 (21 %) of patients in this series required craniotomy following SRS.
Fractionated Stereotactic Radiotherapy
When introduced by Leksell more than 50 years ago (49), stereotactic radiosurgery was intended as a means of creating a "radiation injury". The intent at that time was to destroy brain tissue, not selectively inactivate tumor cells intertwined with normal brain tissue. In an attempt to decrease complications through normal tissue repair and to potentially increase efficacy by allowing reoxygenation and cell cycle reassortment, several centers have treated small series of patients with F-SRT.
Often these series are of patients with recurrent, previously irradiated, lesions where there was a concern for toxicity.
33 patients were treated at the Royal Marsden Hospital with F-SRT for recurrent primary brain tumors (50) . This was a dose escalation study conducted from January 1989 to July 1994. All of these patients had been previously irradiated. Doses ranged from 4 daily fractions of 5Gy to 10 5Gy fractions. The median survival ofthe twenty-one patients with recurrent highgrade gliomas (II AA, IOGBM) was 9.6 months. A matchedpair analysis was performed using patients treated for their recurrence with nitrosourea-based chemotherapy. There was a small, statistically significant, difference in median survival. Late toxicity (not graded) was seen in 36% of the patients.
At Thomas Jefferson University, from November 1994 to September 1996, 20 patients with recurrent (or persistent) high grade gliomas following external beam radiation were treated with a regimen of F-SRT (51) . Three different regimens were used: 24Gy in daily fractions of 3Gy, 30Gy in daily fractions of 3Gy and 35Gy in daily fractions of 3.5Gy. Median survival from the completion of F-SRT was 10.5 months. There were no grade 3-4 acute or late toxicities.
Between April 1991 and January 1998,71 patients with recurrent tumors (13% anaplastic oligodendrogliomas, 87% highgrade astrocytomas, 15% of these were dedifferentiated lowgrade tumors) were treated at the University of Minnesota Hospital. 46 of the patients in this retrospective review were treated with SRS and 25 with F-SRT (52) . For the SRS cases, the median minimum peripheral dose was 17Gy. F-SRT was delivered to a median of 37.5 Gy in 15 fractions. The median survival from stereotactic irradiation was II months for SRS and 12 for F-SRT (p=0.3). Acute complications were seen in 40% of both groups. Late complications (clinical/pathological necrosis or cranial nerve palsy) were seen more commonly in the SRS group -30% vs. 8% (p<0.05). The authors concluded that as the F-SRT group had worse prognostic factors, a similar median survival and less late toxicity, it might represent a better treatment option for recurrent high-grade gliomas.
The same issues of bias that plagued the experience with single fraction SRS apply to the younger experience utilizing F-SRT. Treatment options for recurrent lesions are numerous.
If stereotactic radiation is used, the choice of fractionation may represent a compromise between convenience and risk of radionecrosis.
A more definitive answer may not soon come for F-SRT. The EORTC and the MRC had jointly initiated a randomized trial of F-SRT in the primary management of high-grade gliomas (53) . The patients eligible for this study were those with s; 4 em WHO grade III-IV gliomas, age < 65 years with a good performance status. These patients were to be randomized to partial brain radiation (54-60Gy) followed or not by F-SRT (4x5Gy daily). This study is currently closed because of poor accrual (Dr Michael Brada, personal communication) .
The use of hypofractionated F-SRT in combination with standard radiation therapy is being tested, in Phase IIII trials, in selected patients with primary GBM. Regine et al. (54) treated 18 previously unirradiated patients with brain tumors using a combination of conventional external beam radiation therapy and a split-course F-SRT. Of these 18 patients, 11 were malignant gliomas. F-SRT dose schedule was based in the residual tumor volume and varied from 7 Gy given 2 to 4 times. F-SRT was delivered pre and post-external beam radiation therapy. Of 15 patients evaluated so far, at a median fol-19W-UP of 15 months excessive toxicity was seen only in the group with larger tumor volumes. Of interest, 38% of the patients requiring reoperation (3/8) were found to have only necrosis without evidence of tumor cells. Cardinale et al. (55) reported on 20 selected patients entered on a Phase II trial of F-SRT for previously untreated GBM. Eligibility criteria included the size of post-operative tumor cavity, including any enhancing areas, to be 6 em or less. F-SRT was combined with standard radiation therapy (50 Gy) and was given once per week during weeks 1 through 4. F-SRT dose was tumor size-dependent and ranged from 6-10 Gy per fraction. At a median follow-up time of 21 months, the median survival was 19 months. Radiation necrosis was found in 62% of patients submitted to reoperation (8 patients) .
Although these results are encouraging and the biological concept of F-SRT is interesting, attempting to deliver a higher dose of irradiation while shortening the overall treatment time to decrease the opportunity of accelerated repopulation of clonogenic cells, it is unlikely that a major improvement in tumor control and survival will be achieved. Currently, the RTOG is conducting a Phase II trial (RTOG BR-0023) testing Dr Cardinale's scheme in patients with primary supratentorial GBM.
Stereotactic Radiotherapy for Low Grade Gliomas
The optimal post-operative therapy for patients with lowgrade gliomas remains controversial. Recently, 3 randomized trials failed to show a radiotherapeutic dose-response for the dose levels studied. EORTC 22844 (56) randomized patients between 45 Gy and 59.4 Gy, the Intergroup trial (57) compared 50.4 Gy to 64.8 Gy and the EORTC 22845 trial (58) evaluated a dose of 54 Gy versus observation and in none of these studies a survival benefit could be significantly demonstrated for the higher dose level.
The use of radiosurgery or F-SRT in LGG has been somewhat limited and only few institutions have reported their experience 121 with this therapeutic approach. Although some authors claim a possible benefit from this approach, the number of patients treated is relatively small, the follow-up is short and a clear-cut improvement in outcome cannot be demonstrated from the available literature. At McGill University, we began in 1987 a program of F-SRT for patients with LGGs and 21 such patients were treated exclusively with this stereotactic technique. Eligible patients were those with small (~40 mm), well-circumscribed, deep-seated, pathologically diagnosed, inoperable
LGG. There were II females and 10 males with a median age of 27 years (range: . F-SRT was delivered on alternate days and a median dose of 42 Gy (range: 37.5-45.5) was given in 6 fractions, over 2 weeks. Details of the technical aspects have been published elsewhere (59, 60) . At a median followup of 7.2 years, the 5-and IO-year and survival rates are 72% and 64%, respectively. A total of9 patients (43%) have shown clear evidence of disease progression. Late toxicities attributable to the procedure were observed in 3 patients, leaving one of them with a persistent hemiparesis. Table II depicts the experience from other centers in the management of LGG with stereotactic techniques. From the available literature and our own experience, it appears that the role of radiosurgery or F-SRT is unclear for patients harboring LGG. The data available do not support routine use of stereotactic radiosurgery, even in selected patients.
Treatment Toxicities
Significant acute complications -i.e., those occurring within days to weeks of treatment -are unusual and generally self-limited. Occasionally an exacerbation of existing symptoms may occur, particularly in patients with moderate brain edema and with larger lesions (3-4 ern) , Most patients will respond to increasing doses of corticosteroids.
Late complications attributable to SRS are usually defined as necrosis within the treatment volume. In patients with GBM, distinguishing radiation-induced necrosis from tumor recurrence is not infrequently a very difficult problem and may lead to an overestimation of the rate of treatmentinduced complications. The rate of reoperation for ranges from 0 (34) to 54% (35) . However, viable cells are identified in the majority of such reoperation specimens. Pure necrosis without residual tumor cells is a rare event.
In the review involving 3 institutions and 115 patients (38) , late complications occurred in 16% of the patients. Radiation necrosis was diagnosed in the majority of the patients (17/19) Table II Results of SRS or F-RT in low-grade gliomas Astro =astrocytoma University, have described the determination of a single number parameter for use during F-SRT that may be used to represent effective dosage to intracranial structures that are irradiated with inhomogeneous dose distribution having steep dose gradients. Evaluating biologically effective dose volume histograms, the authors obtained an integral biologically effective (IBED) for each case and demonstrated a threshold value for late damage to the brain stem consistent with similar thresholds that have been determined for external beam radiation therapy. Using aJ~ratio of 2.5 as representative of the dose-response of brain stem tissue, they were able to establish a threshold value in the region of 60GY2.5' The determination of the IBED can be a valuable parameter to be used as a guide to determine the appropriate treatment volume and fractionation regimen that will minimize toxicity to surrounding vital structures in patients undergoing F-SRT.
Future Directions in Stereotactic Radiation for Glial Neoplasms
New strategies in the application of stereotactic radiation for malignant gliomas include.-changes in planning and fractionation, concurrent use of chemotherapy, use of radiation modifiers and biologic agents.
In an attempt to increase treatment intensity, the RTOG currently has open a small Phase IT study of EBRT (50Gy in daily fractions of 2Gy) with a concomitant F-SRT boost followed by 6 months of BCNU chemotherapy (RTOG BR-0023). The RTOG trial is accruing patients with lesions up to 6cm in maximal diameter and is treating to 2 dose levels (7Gy x 4 for lesions~4 em and 5Gy x 4 for larger lesions). As of December 2002, this trial had accrued 41 patients (goal, 76 patients).
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With the use of relocatable stereotactic immobilization devices and advances in treatment planning, the lines between F-SRT and EBRT are becoming blurred. At McGiIl University, we are currently investigating the use of intensity modulated radiation therapy to deliver treatment plans were the enhancing lesions receive 60Gy in 20 fractions while the areas at highest risk for microscopic contamination receive the same total dose in 3.0 fractions (62) . The first 20 patients treated with this regimen had a median survival of 8.1 months. With a median follow-up of 7 months, no late toxicity has been observed.
Current literature reflects a limited experience combining chemotherapy with F-SRT. The results of these Phase I trials may support the feasibility of concurrent chemotherapy but, if the European intergroup trial fails to demonstrate a benefit to F-SRT, the approach will likely fade in favor of integrating new agent with conventional radiation.
A phase I trial (NCI-T99-0041) is investigating the sensitization of SRS with Gadolinium Texaphyrin. In this trial GBM patients with a KPS > 60 and a tumor < 4 ern are treated with conventional EBRT, foIlowing EBRT an IV infusion of Gadolinium Texaphyrin is given 3 hours prior to SRS.
Other treatment strategies brewing in the laboratories of the University of Pennsylvania include radioprotection of normal tissue (63, 64) or tumor sensitization through gene transfer (65) . Glioblastoma has been a frustrating disease for investigators, only time will tell which strategies will make it into clinical practice.
Conclusion
The best evidence currently available does not support an improvement in outcome from the use of SRS for primary glioblastoma multiforme. Despite the modest benefits achieved by escalating EBRT dose to match normal tissue tolerance, it is unlikely that variations in fractionation, total dose or treatment delivery will lead to a significant change in the outcome of patients with GBM. The somewhat limited experience in LGG also indicates a lack of benefit for patients treated with stereotactic radiosurgery or F-SRT.
For a very select group of patients with recurrent disease, F-SRT may represent a safe, reasonable treatment. For recurrent high-grade gliomas other treatment modalities have been tested in phase III trials and only prospective investigation will define the exact role of stereotactic radiation.
